Concepedia

Joseph G. Reynolds

JG

8

Publications

588

Citations

8

H-Index

2012

Active since

Affiliations

Merrimack Pharmaceuticals (United States)(Current)

Indiana University – Purdue University Indianapolis

Acceleron Pharma (United States)

Dana-Farber Cancer Institute

The University of Texas MD Anderson Cancer Center

Joseph G. Reynolds is an author at Merrimack Pharmaceuticals (United States) specializing in oncology, medicine, and cancer therapeutics.

Top concepts

Publications per year

2012–2022

8

Publications

8

HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer

Kathy D. Miller, Javier Cortés, Sara A. Hurvitz et al. · BMC Cancer · 2016 · 153 citations · Full text

Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study

Pamela N. Münster, Ian E. Krop, Patricia LoRusso et al. · British Journal of Cancer · 2018 · 117 citations · Full text

HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity

Joseph G. Reynolds, Elena Geretti, Bart S. Hendriks et al. · Toxicology and Applied Pharmacology · 2012 · 112 citations

, , +7

A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia

Aaron T. Gerds, Alessandro M. Vannucchi, Francesco Passamonti et al. · Blood · 2019 · 66 citations

Impact of Tumor HER2/ERBB2 Expression Level on HER2-Targeted Liposomal Doxorubicin-Mediated Drug Delivery: Multiple Low-Affinity Interactions Lead to a Threshold Effect

Bart S. Hendriks, Stephan G. Klinz, Joseph G. Reynolds et al. · Molecular Cancer Therapeutics · 2013 · 65 citations

, , +26

Rows per page

1–5 of 8